Normal Likelihood and Conjugate Prior Sample Clauses

Normal Likelihood and Conjugate Prior. As explained in the background, after a logarithm transformation, the Armitage-Doll mul- tistage carcinogenesis model can be written as the format of log-linear model: log(r) = α + (s − 1) log(t). To simplify the expression, the above linear model can be expressed as y = Xβ + ϵ, where y is an n × 1 vector of observations, X is an n × p design matrix and β is a p × 1 vector of parameters and ϵ an n × 1 vector of random errors. In this example, y = log(r), X = (1, log(t)), and β = (α, s − 1)r. In most scenarios, the error terms ϵ are assumed have a N (0, σ2) distribution and the model is described as the normal linear model where y|β, σ2 ∼ N (Xβ, σ2 I) and I is an n × n identity matrix. The likelihood takes the format of f (y|β, σ2) = (2πσ2)—n/2 exp{−(y − Xβ)r(y − Xβ)/(2σ2)}. The Normal-inverse-gamma (NIG) prior is then employed to define parameters β and σ2 in the form of f (β, σ2) ∝ (σ2)—(d+p+2)/2 exp{−[(β − m)rV —1(β − m) + a]/(2σ2)}, where a, d ∈ R. The prior distribution can be written as (β, σ2) ∼ NIG(a, d, m, V ) and the normal-inverse gamma prior can be equivalently derived from σ2 ∼ IG(a, d) and β|σ2 ∼ N (m, σ2 V ). We can also obtain weak prior information about (β, σ2) within the conjugate family by letting prior variances go to infinity [X’Xxxxx, 1994]. If parameters a and d in the inverse gamma prior for variance σ2 are taken to be 0, we can derive an improper prior for σ2 as f (σ2) ∝ σ—2 based on the probability density function for inverse gamma distribution. In addition, if we let V —1 → 0, we can simplify the joint prior f (β, σ2) ∝ σ—(p+2). The posterior can be derived after combining the likelihood and the prior. By the conjugate structure, the posterior is still with normal-inverse-gamma f (β, σ2|y) ∝ f (y|β, σ2)f (β, σ2) ∝ (σ2)—(d+n+p+2)/2 exp{−Q/(2σ2)} where Q = (y − Xβ)r(y − Xβ) + (β − m)rV —1(β − m) + a = (β − m∗)r(V ∗)—1(β − m∗) + a∗, and the posterior distribution can be written as (β, σ2|y) ∼ NIG(a∗, d∗, m∗, V ∗) where V ∗ = (V —1 + XrX)—1, m∗ = (V —1 + XrX)—1(V —1m + Xry), a∗ = a + mrV —1m + yry − (m∗)r(V ∗)—1m∗, d∗ = d + n. If XrX is non-singular, the posterior estimate of β which is E(β|y) = m∗ can be written as m∗ = (V —1 + XrX)—1(V —1m + XrXβˆ) = (I − A)m + Aβˆ, where A = (V —1 + XrX)—1XrX. In the log-normal Armitage-Doll model, we have logti n (XrX)—1 = ,. Σ Σ logti Σ —1   Σ (logti)2 , . and Xry = . X xxxxx . ,  logti logri then we can calculate the classical estimate βˆ = (XrX)—1(Xry) and the posterior mean of β is a w...
AutoNDA by SimpleDocs

Related to Normal Likelihood and Conjugate Prior

  • Expected Outcomes The educational goals and objectives for improving student achievement, including how much academic improvement students are expected to show each year, how student progress and performance will be evaluated and the specific results to be attained, as described in Section 5a of the application: Student Performance, Assessment and Evaluation.

  • Expected Outcome With this waiver, the school will be able to implement its program and evaluate its teachers in accordance with its Performance Appraisal System, which is designed to produce greater accountability and be consistent with the school’s goals and objectives. This will benefit staff members as well as students and the community. Non-Automatic Waivers: Statute Description and Rationale and Replacement Plan

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.

  • Environmentally Preferable Procurement Policy The Environmentally Preferable Procurement Policy, along with a brief policy description, is located on the City’s website at the following link: xxxx://xxx.xxxxxxxxx.xxx/esd/natural-energy-resources/epp.htm. Environmental procurement policies and activities related to the completion of any Work will include, whenever practicable, but are not limited to:  The use of recycled and/or recyclable products in daily operations (i.e. 30%, 50%, 100% PCW paper, chlorine process free, triclosan free hand cleaner, etc.);  The use of energy-star compliant equipment;  The use of alternative fuel and hybrid vehicles, and implementation of protocols aimed at increasing the efficiency of vehicle operation;  The implementation of internal waste reduction and reuse protocol(s); and  Water and resource conservation activities within facilities, including bans on individual serving bottled water and the use of compostable food service products.

  • Target Population The Grantee shall ensure that diversion programs and services provided under this grant are designed to serve juvenile offenders who are at risk of commitment to Department.

  • Initial Forecasts/Trunking Requirements Because Verizon’s trunking requirements will, at least during an initial period, be dependent on the Customer segments and service segments within Customer segments to whom CSTC decides to market its services, Verizon will be largely dependent on CSTC to provide accurate trunk forecasts for both inbound (from Verizon) and outbound (to Verizon) traffic. Verizon will, as an initial matter, provide the same number of trunks to terminate Reciprocal Compensation Traffic to CSTC as CSTC provides to terminate Reciprocal Compensation Traffic to Verizon. At Verizon’s discretion, when CSTC expressly identifies particular situations that are expected to produce traffic that is substantially skewed in either the inbound or outbound direction, Verizon will provide the number of trunks CSTC suggests; provided, however, that in all cases Verizon’s provision of the forecasted number of trunks to CSTC is conditioned on the following: that such forecast is based on reasonable engineering criteria, there are no capacity constraints, and CSTC’s previous forecasts have proven to be reliable and accurate.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Study Population ‌ Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months post enterostomy closure, following enterostomy closure (12-month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 month of overall study duration).

  • Bidder Supplied Samples The Commissioner reserves the right to request from the Bidder/Contractor a representative sample(s) of the Product offered at any time prior to or after award of a contract. Unless otherwise instructed, samples shall be furnished within the time specified in the request. Untimely submission of a sample may constitute grounds for rejection of Bid or cancellation of the Contract. Samples must be submitted free of charge and be accompanied by the Bidder’s name and address, any descriptive literature relating to the Product and a statement indicating how and where the sample is to be returned. Where applicable, samples must be properly labeled with the appropriate Bid or Contract reference. A sample may be held by the Commissioner during the entire term of the Contract and for a reasonable period thereafter for comparison with deliveries. At the conclusion of the holding period the sample, where feasible, will be returned as instructed by the Bidder, at the Bidder’s expense and risk. Where the Bidder has failed to fully instruct the Commissioner as to the return of the sample (i.e., mode and place of return, etc.) or refuses to bear the cost of its return, the sample shall become the sole property of the receiving entity at the conclusion of the holding period.

  • MSAA Indicator Technical Specification Document This Agreement shall be interpreted with reference to the MSAA Indicator Technical Specifications document.

Time is Money Join Law Insider Premium to draft better contracts faster.